Definium Therapeutics Phase 3 Voyage Study Of DT120 ODT Met Primary & Key Secondary Efficacy Endpoints
DFTX•Further company coverage
Further company coverage: DFTX.O
Phase 3 Voyage study met primary and key secondary endpoints
Aug. 12 (Reuters) - Definium Therapeutics Inc DFTX.O:
- Definium Therapeutics: Phase 3 Voyage study of DT120 ODT met primary & key secondary efficacy endpoints
- Definium Therapeutics: DT120 ODT generally well tolerated in study, no new safety signals including no suicidality signal
- Definium Therapeutics: Participants on DT120 ODT achieved statistically significant reduction in Hamilton Anxiety Rating Scale score
